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Jun Qian, Chen Heidi, Chanjuan Shi,
Rosana Eisenberg, Pierre Massion Vanderbilt
University Medical Center, Nashville, TN
Small cell lung cancer (SCLC) is a high grade poorly
differentiated neuroendocrine carcinoma of the lung
responsible forw15% of diagnosed lung cancers and up
to 25% of lung cancer deaths. Treatment paradigms in
small cell lung cancer have not changed signiﬁcantly in
the last 20 years. Advances in targeted therapies for
SCLC are sorely needed. Somatostatin receptors (SSTR)
are neuroendocrine associated G protein-coupled re-
ceptors associated with multiple tumor types and which
have effects on cell cycling, angiogenesis, apoptosis, and
growth factors. They canonically signal by inhibition of
adenylate cyclase, calcium inﬂux, and act through
downstream MAPK and Akt as well as other downstream
kinases. We evaluated SSTR2 expression by IHC staining
and western blotting of multiple cell lines and tumor
tissues and found high expression in multiple neuroen-
docrine lung carcinomas including classical and variant
SCLC lines. Given the high level of SSTR2 expression
found in most SCLC lines, we hypothesized that this
signaling pathway stimulates growth and survival of
these tumor cells. We followed these preliminary studies
with an assessment of 98 SCLC patients whose tumor
IHC was subdivided into high or low SSTR2 expressing
tumors by continuous IHC scoring. Low SSTR2 tumors
had a better prognosis with a median survival in limited
stage disease of 36 months compared to 12 months in
the SSTR2 high expressing SCLCs suggesting that SSTR2
expression has clinical relevance in SCLC progression.
The hazard ratio was 0.45 with a p<0.05. This led to
further experiment to interrogate the mechanism and
function of SSTR2 in SCLC. We established multiple
stable SSTR2 shRNA knockdown lines including bron-
chial carcinoid, and multiple adherent SCLC lines. SSTR2
knockdown led to up to 3 fold changes in cell viability
in vitro with reduced proliferation in multiple cell cul-
ture lines and constructs as well as apoptosis in H1048
cells. Metabolic testing with Seahorse mito stress kitsconcurred with signiﬁcant differences in mitochondrial
respiration and metabolic activity in the SSTR2 knock-
down cell lines with a slightly increased basal metabolic
rate and a signiﬁcant greater than 75% increase in
maximal respiration compared to the control scrambled
construct cell line. We are actively pursuing metabolic
studies in SCLC and will expand this work to evaluate
ADP/ATP and AMP/ATP ratios to determine if aberrant
energy homeostasis may contribute to the observed cell
death in this metabolically active cell population.
Collectively, this data brings new interest to SSTR2
signaling as a pathway target for therapy in a subset of
SCLC and suggests potential metabolic targets in SCLC.An epigenetic switch leads to EMT
memory in chronic inﬂammation in
non-small cell lung cancerRui Li, Stephanie Ong, Kostyantyn Krysan,
Linh Tran, Stacy Park, Tonya Walser,
Jing Zhe, Steven Dubinett UCLA, Los Angeles, CA
Metastases are the major causes of death in cancer pa-
tients. Prevention and therapy against metastatic or
dormant tumor cells have achieved limited success due
to gaps in our knowledge regarding the underlying
mechanisms. Dysregulated inﬂammation is associated
with the development and progression of lung cancer.
Lung cancer patients with increased levels of inﬂam-
matory mediators or inﬂammatory cells have poorer
outcomes. It has been shown that inﬂammatory cyto-
kines in the tumor microenvironment can promote
cancer metastasis and facilitate formation of stem-like
malignant cells. However, the mechanisms of these ef-
fects in lung cancer have not been fully understood.
Recently, we have found that a subset of NSCLC cells
undergo epithelial-to-mesenchymal transition (EMT) in
the presence of cytokines including IL-1b, TNF-a and
TGF-b (within 7 days). This occurs concomitantly with
increased cell migration and invasion. Surprisingly,
chronic exposure to these inﬂammatory cytokines leads
to EMT memory, referring to the phenomenon that cells
are able to maintain EMT despite withdrawal of the
original stimulus. Intriguingly, EMT memory cannot be
induced by acute cytokine exposure and the signaling
pathways (JNK/ERK) and transcription factors (fra-1/
slug) mediating the acute EMT are necessary to establish
but not required to maintain EMT memory. Further
studies demonstrated that EMT memory is due to a dy-
namic alteration of histone modiﬁcations and subse-
quent DNA methylation during chronic IL-1b exposure.
Importantly, EMT memory also allows cells to irrevers-
ibly become migratory and invasive. In a pilot study, we
February 2016 Abstracts S31sequenced the miRNA in these cells and found that cells
with EMT memory have distinct miRNA proﬁle
compared to cells with transient EMT, suggesting that
the epigenetic switch upon chronic IL-1b exposure leads
to selective gene expression. These ﬁndings, for the ﬁrst
time, demonstrate a unique feature in chronic inﬂam-
mation that allows cells to metastasize and eventually
grow in distant organs, suggesting that these cells may
serve as a reservoir for tumor metastasis and relapse.
The intent of this study is to ultimately identify targets to
intervene in preventing and treating metastatic behavior
in lung cancer.
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Background: The randomized, double-blind, placebo-
Controlled Study of Lanreotide Antiproliferative
Response in Neuroendocrine Tumors (CLARINET)
showed that treatment with the somatostatin analog
(SSA) lanreotide depot was associated with signiﬁcantly
prolonged progression-free survival (PFS) vs placebo
(PBO) in gastroenteropancreatic neuroendocrine tumors
(GEP-NETs), leading to FDA approval. Like GEP-NETs,
lung NETs express somatostatin receptors.
Methods: This multi-institutional study will enroll an
anticipated216patientswith lowgrademetastatic and/or
un-resectable NETs that have positive somatostatin scin-
tigraphy and who are treatment naïve or have had no
more than 1 course of systemic chemotherapy (cytotoxic,
molecular targeted therapy or interferon). Patients will be
randomized 2:1 to receive lanreotide depot 120 mg via
deep subcutaneous injection plus best standard of care or
PBO. An estimated 175PFS events (disease progression or
death) on both arms will provide a 90% power to detect a
statistically signiﬁcant treatment effect using a two-sided
log rank test at a signiﬁcance level of a¼0.05.
Results: Anticipated results include the primary
endpoint of PFS in both arms, as well as secondaryendpoints which include objective radiologic response
rate, overall survival, effects on plasma chromogranin A,
and safety/tolerability.
Conclusion: Therapeutic agents for the treatment of
lung NETs are currently limited. This study will provide
data on the efﬁcacy of lanreotide depot for patients with
these understudied malignancies.Heterogeneity of programmed cell
death-ligand 1 expression in lung
cancerAaron Mansﬁeld, Stephen Murphy,
Tobias Peikert, Joanne Yi, George Vasmatzis,
Dennis Wigle, Marie Christine Aubry Mayo Clinic,
Rochester, MN
Introduction: The expression of programmed cell death
ligand 1 (PD-L1) provides limited predictive value in
identifying patients most likely to respond to immuno-
therapy. Since the heterogeneity of PD-L1 expression
may lead to sampling error and the misclassiﬁcation of
PD-L1 status, we assessed the heterogeneity of PD-L1
expression in paired resected multifocal lung cancers
with the hypothesis that expression is heterogeneous.
Methods: PD-L1 was assessed by immunohistochem-
istry (CellSignaling #13684 clone E1L3N). Five percent
or greater membranous expression was considered
positive. A chromosomal rearrangement-based next-
generation sequencing approach was used to deﬁne
paired lesions as independent primaries or related le-
sions. Descriptive and agreement statistics were used for
analysis.
Results: A total of 67 multifocal lung cancers from 32
patients were sequenced and stained for PD-L1. There
was agreement of PD-L1 expression by the tumor cells in
paired lesions of 20 patients, and disagreement of PD-L1
expression by the tumor cells in paired lesions of 12
patients (kappa¼0.01). Sequencing identiﬁed that 23
patients had independent primary lung cancers and that
nine patients had related cancers. Amongst the patients
with independent cancers, there was agreement of
PD-L1 expression by the tumor cells in paired lesions of
12 patients, and disagreement of PD-L1 expression by
the tumor cells in paired lesions of 11 patients
(kappa¼0.31). Amongst the patients with related lung
cancers, there was agreement of PD-L1 expression by the
tumor cells in paired lesions of 8 patients, and
disagreement of PD-L1 expression by the tumor cells in
paired lesions of 1 patient (kappa¼0.73).
Conclusion: Overall, the expression of PD-L1 is hetero-
geneous amongst paired multifocal lung cancers, but
